1
Prevenar 13 is well established on the National Immunisation Program
for the protection of infants (> 6 weeks) from pneumococcal disease. 2
Prevenar 13 is also indicated for use in adults. 1
The Australian Immunisation Handbook recommends all patients at
the highest risk of pneumococcal disease (known as Category A)
be given Prevenar 13. 2 Refer to the Pneumococcal Disease section
of the Handbook and help protect your highest-risk patients today. 2
To learn more about Prevenar 13 call 1800 675 229.
PBS Information: This product is listed on the National Immunisation Programme (NIP)
for children only and is not listed on the PBS. Refer to the NIP Schedule.
BEFORE PRESCRIBING, PLEASE REVIEW THE PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT IN THIS PUBLICATION.
Limited safety and immunogenicity data on PREVENAR 13 are available for patients with sickle cell disease, allogeneic hematopoietic stem cell transplant, or HIV infection, and are not available for other immunocompromised
patient groups. Efficacy/effectiveness has not been established. Vaccination should be considered on an individual basis. Immunocompromised individuals or individuals with impaired immune responsiveness due to
the use of immunosuppressive therapy may have a reduced antibody response to PREVENAR 13. Immunisation schedules for PREVENAR 13 should be based on official recommendations. References: 1. PREVENAR 13 ®
Approved Product Information. 2. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook 10th Ed (2017 Update). Canberra: Australian Government Department of Health, 2017.
Available at www.immunise.health.gov.au. Accessed February 2018. ®Registered trademark. Pfizer Australia Pty Limited, 38–42 Wharf Road, West Ryde, NSW 2114. PP-PNA-AUS-0070. PFA2435FP/MO-F. 02/18 S&H.